A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
Status: Recruiting
Location: See all (29) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Mean eGFR greater than or equal to 30 mL/min/1.73m2
• Clinical evidence of active kidney disease
• Treated with supportive care including an ACE inhibitor or ARB if applicable
• Willing to receive required vaccinations
• Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy
Locations
United States
Florida
ADARx Clinical Site
RECRUITING
Doral
ADARx Clinical Site
RECRUITING
Miami
ADARx Clinical Site
RECRUITING
Pembroke Pines
Iowa
ADARx Clinical Site
RECRUITING
Iowa City
Louisiana
ADARx Clinical Site
RECRUITING
Shreveport
Michigan
ADARx Clinical Site
RECRUITING
Shelby
New York
ADARx Clinical Site
RECRUITING
Great Neck
Ohio
ADARx Clinical Site
RECRUITING
Columbus
South Dakota
ADARx Clinical Site
RECRUITING
Dakota Dunes
Texas
ADARx Clinical Site
RECRUITING
Dallas
ADARx Clinical Site
RECRUITING
Houston
Other Locations
Australia
ADARx Clinical Site
RECRUITING
Liverpool
ADARx Clinical Site
RECRUITING
Sydney
ADARx Clinical Site
RECRUITING
Wollongong
ADARx Clinical Site
RECRUITING
Woolloongabba
Hong Kong Special Administrative Region
ADARx Clinical Site
RECRUITING
Hong Kong
ADARx Clinical Site
RECRUITING
Shatin
Republic of Korea
ADARx Clinical Site
RECRUITING
Cheonan
ADARx Clinical Site
RECRUITING
Daegu
ADARx Clinical Site
RECRUITING
Gyeonggi-do
ADARx Clinical Site
RECRUITING
Seoul
ADARx Clinical Site
RECRUITING
Seoul
ADARx Clinical Site
RECRUITING
Seoul
ADARx Clinical Site
RECRUITING
Seoul
ADARx Clinical Site
RECRUITING
Wŏnju
Spain
ADARx Clinical Site
RECRUITING
Barcelona
ADARx Clinical Site
RECRUITING
Madrid
ADARx Clinical Site
RECRUITING
Seville
United Kingdom
ADARx Clinical Site
RECRUITING
Newcastle Upon Tyne
Contact Information
Primary
Tracy Nguyen
info@adarx.com
877-232-7974
Time Frame
Start Date: 2025-08-28
Estimated Completion Date: 2029-06
Participants
Target number of participants: 45
Treatments
Experimental: ADX-038 Dose Level 1 - IgAN
Experimental: ADX-038 Dose Level 1 - C3G
Experimental: ADX-038 Dose Level 2 - IgAN
Related Therapeutic Areas
Sponsors
Leads: ADARx Pharmaceuticals, Inc.